They further uncovered that AS-tDR-007333 promoted NSCLC malignancy by activating MED29 through two mechanisms, either interacting with HSPB1, enhancing H3K4me1 and H3K27ac in MED29 promoter and activating MED29 expression, or stimulating the expression of transcription factor ELK4 to bind to MED29 promoter and increase its transcription [139]. This evidence concerns the gene MED29 and non-small cell lung carcinoma.